Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...

Pfizer's built from many pieces that are moving in opposite directions. To make sure this stock isn't a yield trap destined to slash its dividend payout in the near term, let's weigh the good news ...

In subpoenaing a former Pfizer Inc. official to appear before the U.S. House Judiciary Committee July 22, Judiciary Chair Jim Jordan, R-Ohio, signaled legislative steps Congress may take in response ...

A federal judge dismissed Acuitas Therapeutics Inc.'s lawsuit seeking to name its scientists as inventors on seven Alnylam Pharmaceuticals Inc. patents tied to Covid-19 vaccine technology, blunting ...

Dr. Philip Dormitzer, former global head of vaccine research and development at Pfizer, has been subpoenaed by the House Judiciary Committee as it investigates Pfizer’s alleged delay in the ...

Chairman Jim Jordan subpoenaed former Pfizer executive Dr. Philip Dormitzer for an investigation into delayed COVID-19 vaccine trial results before the 2020 election.

(RTTNews) - XtalPi (2228.HK) announced an expanded research collaboration with Pfizer (PFE) to develop a next-generation molecular modeling platform for drug discovery. The initiative aims to ...

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an allegation that clinical testing related to the development of the ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and ...